---
category: trading
circular_id: 653a6c38df21cc87
date: '2025-12-30'
description: 'BSE revokes the suspension in trading of equity shares of Rekvina Laboratories
  Limited (Scrip Code: 526075), allowing normal trading to resume.'
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F3349061-F124-4E89-A312-EFE0B6AC1B6C}&noticeno=20251230-9&dt=12/30/2025&icount=9&totcount=55&flag=0
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Revocation of trading suspension is significant for shareholders and
  traders of Rekvina Laboratories as it allows normal trading to resume, but has limited
  broader market impact as it affects a single scrip.
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20251230-9&attachedId=87682fdc-cc89-475e-a9de-1cb2933a1fdd
processing:
  attempts: 1
  content_hash: 24465082c2b46eaf
  processed_at: '2025-12-30T15:52:27.841390'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-12-30T07:36:30+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={F3349061-F124-4E89-A312-EFE0B6AC1B6C}&noticeno=20251230-9&dt=12/30/2025&icount=9&totcount=55&flag=0
severity: medium
source: bse
stocks:
- REKVINA
tags:
- revocation
- suspension
- equity-shares
- rekvina-laboratories
- trading-resumption
- pharmaceutical
title: Revocation of Suspension in Trading of Equity Shares of Rekvina Laboratories
  Ltd
---

## Summary

BSE has revoked the suspension in trading of equity shares of Rekvina Laboratories Limited (Scrip Code: 526075, ISIN: INE092O01028). The company, engaged in the pharmaceutical industry providing quality medication at affordable prices, can now resume normal trading on the exchange.

## Key Points

- Trading suspension revoked for Rekvina Laboratories Limited
- Scrip Code: 526075
- ISIN: INE092O01028
- Company operates in pharmaceutical industry
- Registered office located in Vadodara, Gujarat
- Manufacturing plant at GIDC Estate, Waghodia, Vadodara
- Group company: Radiant Parenterals Limited
- Current operational status: Active
- Managing Director: Amit Mukesh Shah (DIN: 01993211)
- Company Secretary: Deepak Khandelwal
- Auditor: M/s. Y.M. Shah & Co. (FRN: 114124W) for period 2024-25 to 2028-29
- Previous auditor: M/s. Jigar Adhyaru & Co. (2019-20 to 2023-24)

## Regulatory Changes

No regulatory changes are introduced by this circular. This is a revocation of a previously imposed trading suspension.

## Compliance Requirements

- Company has paid listing fees to BSE
- Company maintains active operational status
- Auditor change was conducted in compliance with statutory term completion requirements

## Important Dates

Circular Date: December 30, 2025

## Impact Assessment

**Market Impact:** Medium - Trading resumption allows shareholders to trade their holdings and provides liquidity to the scrip. This is positive for existing shareholders who were unable to exit positions during suspension.

**Operational Impact:** The company can now access capital markets normally and its shares will be available for trading, improving market confidence in the company's compliance status.

**Investor Impact:** Positive for existing investors who can now trade their holdings. The revocation suggests the company has addressed the issues that led to the original suspension.